Navigation Links
Micromet Key Events for 2009
Date:1/5/2009

ested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of BiTE antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of pa
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Expands Committed Equity Financing Facility to $75 Million
2. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
3. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
6. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
10. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... epigenetic drivers of cancer, will be presenting at the 2015 ... 1:55 p.m. ET (10:55 a.m. PT) in New ... president and CEO of Mirati, will provide a corporate overview. ... be accessible on the "Investors" page of Mirati,s corporate website ...
(Date:8/4/2015)... MADISON, Wis. , Aug. 4, 2015 /PRNewswire/ ... an agreement with Restore Health, a company specializing ... of a double-blind clinical trial, designed to evaluate ... drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). ... Ironshore. Restore Health originally partnered with ...
(Date:8/3/2015)...  Luminex Corporation (NASDAQ: LMNX ) today announced ... 2015.  Financial and operating highlights for the quarter include ... revenue by 6 percent to $58.9 million, over the ... 2015 assay revenue by 22 percent to $24.2 million ... , Increased Q2 2015 royalty revenue by 17 percent ...
Breaking Medicine Technology:Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the launch of a new product suite designed to provide pharmaceutical and healthcare ... trends based on multi-sourced and cross-referenced data from regulatory filings (including the FDA ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Well videos to preparing high school athletes for fall sports. , In a concise video ... , What steps to take to help prevent injuries , ...
Breaking Medicine News(10 mins):Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) ... as ibuprofen during the first stage of their pregnancy ... suggests. "We,re seeing a 2.4-fold increased risk ... pregnancy," said Anick Berard, senior author of a paper ...
... U.S. Food and Drug Administration (FDA) clears the path for ... estimating the risk of ovarian cancer in women with a ... and use of a combination of blood tests for proteins ... (ROMA). Research demonstrates that examining levels of HE4 and CA125 ...
... PARK, Md. - Amid ongoing concerns about E. coli, ... take a unique approach to make imports bound for ... those foods intensive, hands-on lab training in U.S. government ... "The more we can get foreign food facilities ...
... German . The stomach bacterium Helicobacter pylori ... gastric cancer, the third most common cause of cancer-related deaths in ... identified a mechanism of Helicobacter pylori that damages the DNA of ... transformation. Gastric cancer is one of the most common and ...
... cells is an effective treatment for patients with malignant ... cells are crucial to the outcome. Researchers from Lund ... the quality of the transplanted cells using ultrasound for ... blood stem cell transplant is often the only treatment ...
... , This release is available in German . ... they react with a suitable behavioural response and do not ... is the case, for example, with patients who suffer from ... from the Max Planck Institute of Psychiatry have discovered two ...
Cached Medicine News:Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:FDA clears biomarker test for ovarian cancer 2Health News:FDA clears biomarker test for ovarian cancer 3Health News:For safer food imports, Teach foreign lab workers US requirements 2Health News:For safer food imports, Teach foreign lab workers US requirements 3Health News:Stomach bacterium damages human DNA 2Health News:Ultrasound improves stem cell transplants 2Health News:Control of fear in the brain decoded 2Health News:Control of fear in the brain decoded 3
... Vitoss engineered to ... porosity and structure. -TCP ... well in spinal arthrodesis ... defects due to trauma ...
... is a synthetic porous ceramic graft material composed ... mineral phase that comprises 70% of human bone. ... scaffold that allows the attachment of bone forming ... networks within granules as well as between each ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Baby Weitlaner retractor, blunt, 4"....
Medicine Products: